X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
male (14) 14
animals (11) 11
endocrinology & metabolism (10) 10
humans (10) 10
type 2 diabetes (10) 10
diabetes (8) 8
rats (8) 8
aged (7) 7
diabetes mellitus, type 2 - drug therapy (7) 7
female (7) 7
glucagon-like peptides - analogs & derivatives (7) 7
middle aged (7) 7
rats, sprague-dawley (7) 7
exenatide (6) 6
kidney diseases (6) 6
kidneys (6) 6
liraglutide (6) 6
risk factors (6) 6
treatment outcome (6) 6
diabetes mellitus (5) 5
drug administration schedule (5) 5
dulaglutide (5) 5
expression (5) 5
glucagon-like peptide-1 (5) 5
glucagon-like peptide-1 receptor - agonists (5) 5
hypertension (5) 5
insulin (5) 5
insulin glargine (5) 5
oxidative stress (5) 5
peripheral vascular disease (5) 5
rodents (5) 5
blood pressure (4) 4
blood pressure - physiology (4) 4
chronic kidney failure (4) 4
diabetes mellitus, type 2 - blood (4) 4
efficacy (4) 4
epidermal growth factor receptors (4) 4
glomerular filtration rate (4) 4
glucagon-like peptides - administration & dosage (4) 4
glucagon-like peptides - therapeutic use (4) 4
glycosylated hemoglobin (4) 4
heme oxygenase (4) 4
heme oxygenase - metabolism (4) 4
hypoglycemic agents - therapeutic use (4) 4
immunoglobulin fc fragments - administration & dosage (4) 4
immunoglobulin fc fragments - therapeutic use (4) 4
kidney - metabolism (4) 4
once-weekly dulaglutide (4) 4
physiology (4) 4
recombinant fusion proteins - administration & dosage (4) 4
recombinant fusion proteins - therapeutic use (4) 4
renal impairment (4) 4
research (4) 4
therapy (4) 4
urology & nephrology (4) 4
abridged index medicus (3) 3
adult (3) 3
ang ii-dependent hypertension (3) 3
biomarkers - blood (3) 3
blood glucose - drug effects (3) 3
blood glucose - metabolism (3) 3
carbon monoxide (3) 3
cardiac & cardiovascular systems (3) 3
clinical trials, phase iii as topic (3) 3
creatinine (3) 3
diabetes mellitus, type 2 - complications (3) 3
diabetes mellitus, type 2 - metabolism (3) 3
diabetes therapy (3) 3
drug therapy (3) 3
enzyme inhibitors - pharmacology (3) 3
estimated glomerular filtration rate (3) 3
exendin-4 (3) 3
glp-1 (3) 3
glucagon (3) 3
glucagon-like peptide-1 receptor - metabolism (3) 3
glucagon-like peptides - adverse effects (3) 3
glycemic control (3) 3
hemoglobin (3) 3
hypoglycemic agents - administration & dosage (3) 3
immunoglobulin fc fragments - adverse effects (3) 3
immunohistochemistry (3) 3
incretin (3) 3
kidney (3) 3
medicine, general & internal (3) 3
patients (3) 3
peptides (3) 3
prospective studies (3) 3
recombinant fusion proteins - adverse effects (3) 3
safety (3) 3
2k1c (2) 2
adolescent (2) 2
alternative transcriptional start (2) 2
ang-ii (2) 2
angiotensin i - metabolism (2) 2
angiotensin ii (2) 2
angiotensin ii - pharmacology (2) 2
angiotensin-ii (2) 2
apoptosis (2) 2
arhgef18 (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cardiovascular Diabetology, ISSN 1475-2840, 02/2016, Volume 15, Issue 1, pp. 38 - 38
Background: Patients with type 2 diabetes (T2D) have a substantial increased risk for cardiovascular (CV) disease and associated mortality than those without... 
Glucagon-like peptide-1 (GLP-1) | Type 2 diabetes | Cardiovascular events | Incretin | MACE | Meta-analysis | METFORMIN | GLYCEMIC CONTROL | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | INTENSIVE GLUCOSE CONTROL | EXENATIDE | FOLLOW-UP | MELLITUS | PEPTIDE-1 ANALOG | RECEPTOR AGONIST DULAGLUTIDE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | Index Medicus
Journal Article
Diabetes, ISSN 0012-1797, 06/2019, Volume 68, Issue Supplement 1, p. 233
In the AWARD-7 study, conducted in T2D and moderate-to-severe CKD, DU treatment was associated with slower decline in estimated glomerular filtration rate... 
End-stage renal disease | Epidermal growth factor receptors | Diabetes mellitus | Population studies | Blood pressure | Kidney diseases | Diabetes | Diabetes mellitus (non-insulin dependent) | Insulin | Glomerular filtration rate
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 03/2017, Volume 19, Issue 3, pp. 436 - 441
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2016, Volume 18, Issue 11, pp. 1138 - 1142
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2019, Volume 21, Issue 6, pp. 1493 - 1497
In patients with type 2 dibetes and moderate‐to‐severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline... 
GLP‐1 | type 2 diabetes | GLP-1 | ENDOCRINOLOGY & METABOLISM | Type 2 diabetes | Insulin glargine | Chronic kidney failure | Body weight | Diabetes therapy | Creatinine | Cystatin | Kidneys | Epidermal growth factor receptors | Cattle | Diabetes mellitus | Cystatin C | Kidney diseases | Diabetes mellitus (non-insulin dependent) | Insulin
Journal Article
DIABETES, ISSN 0012-1797, 07/2018, Volume 67, Issue Supplement 1, p. 1557
Conference Proceeding
Cardiovascular diabetology, 02/2016, Volume 15, p. 38
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 08/2018, Volume 6, Issue 8, pp. 605 - 617
Journal Article
Journal of medical economics, 02/2019, p. 1
Examine healthcare costs across chronic kidney disease (CKD) stages for US patients with type 2 diabetes (T2D). IQVIA Real World Data Adjudicated Claims linked... 
Journal Article
Journal of Leukocyte Biology, ISSN 0741-5400, 07/2018, Volume 104, Issue 1, pp. 135 - 145
Genomic, transcriptomic and proteomic databases indicate that the N‐terminal 322 residues encoded by the presumptive LOC100996504 gene, which is adjacent to... 
granulocyte | alternative transcriptional start | ARHGEF18 | LOC100996504 | guanine nucleotide exchange factor | p114‐GEF | p114-GEF | guanine nucleotide exchange factor (GEF)
Journal Article
DIABETES, ISSN 0012-1797, 07/2018, Volume 67, Issue Supplement 1, p. 1066
Conference Proceeding
American Journal of Physiology: Cell Physiology, ISSN 0363-6143, 12/2006, Volume 291, Issue 6, pp. H2772 - H2778
Heme oxygenases (HO-1 and HO-2) catalyze the conversion of heme to carbon monoxide (CO), iron, and biliverdin. CO causes vasorelaxation via stimulation of... 
Journal Article
JOURNAL OF LEUKOCYTE BIOLOGY, ISSN 0741-5400, 07/2018, Volume 104, Issue 1, pp. 135 - 145
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2023 - 2028
Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion.... 
beta‐cell function | GLP | type 2 diabetes | dulaglutide | 1 receptor agonist | beta-cell function | GLP-1 receptor agonist | METFORMIN | EFFICACY | SAFETY | EXENATIDE | INSULIN | GLUCAGON-LIKE PEPTIDE-1 | LIRAGLUTIDE | GLUCOSE | ENDOCRINOLOGY & METABOLISM | ONCE-WEEKLY DULAGLUTIDE | DYSFUNCTION | Glycated Hemoglobin A - analysis | C-Peptide - blood | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Diabetes Mellitus, Type 2 - metabolism | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Glucagon-Like Peptide-1 Receptor - metabolism | Insulin-Secreting Cells - metabolism | Hypoglycemic Agents - administration & dosage | Female | Immunoglobulin Fc Fragments - therapeutic use | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Recombinant Fusion Proteins - administration & dosage | Insulin Secretion - drug effects | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Drug Administration Schedule | Insulin Resistance | Biomarkers - blood | Disease Progression | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Aged | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Cohort Studies | Type 2 diabetes | Medical research | Pancreatic beta cells | Peptides | Blood sugar | Glycosylated hemoglobin | Medicine, Experimental | Fasting | Glucagon | Secretion | Diabetes mellitus | Glucose | Insulin | Patients | Blood | Beta cells | Lymphocytes B | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Index Medicus | GLP‐1 receptor agonist | Brief Report | Brief Reports
Journal Article